With new additions, Bina Technologies poised to impact the clinical
research market with best-in-class analytical workflows
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
Technologies, the genomic big data science company accelerating
personalized medicine, today announced the expansion of their advisory
board and commercial team. This announcement marks the latest in the
company’s initiatives to significantly improve genomics data analysis
workflows used in clinical research. Bina has expanded its Scientific
Advisory Board, adding four luminaries with deep experience in clinical
genomics research. The company has also brought on two commercial team
leaders, tapping into their combined 40+ years of experience driving
revolutionary technologies into the genomics market.
In addition to existing SAB members Dr. Wing Wong, a professor of
Statistics and of Health Research and Policy at Stanford University; Dr.
Garry Nolan, Professor of Microbiology and Immunology at the Stanford
School of Medicine and co-founder of several biotechnology companies
including Rigel and Nodality; and Dr. Wawrzynek, Professor of
Engineering and Computer Sciences at UC Berkeley, Bina has added
clinical genomicists Dr. Robert Green, Dr. Shashikant Kulkarni, Dr. Rong
Chen, and bioinformaticist Dr. Mark Gerstein. The SAB now includes an
impressive team of experts across the disciplines of clinical research,
genomics, computer science and engineering, and bioinformatics.
“The extensive experience of our new SAB members, each having
distinguished themselves in clinical research, will be one of the
driving factors in achieving Bina’s goal of revolutionizing clinical
care by providing researchers with the tools to quickly and easily
analyze large genomic data, ultimately helping with patient diagnosis,
prognosis and therapeutic selection,” said Narges Bani Asadi, CEO of
Bina Technologies. “These experts will help assure that Bina’s
analytical tools will enable the clinical research community to
revolutionize medical care.”
The expanded SAB will offer expert guidance in providing tools that
address the fields’ significant challenges around handling complex
next-generation sequencing data sets. With the expanded SAB and new
commercial leaders, Bina will focus on delivering powerful, accurate and
easy-to-use analytical tools that enable the clinical research community.
“The clinical and research communities working in genomics need tools
that make it faster and easier to manage the massive amounts of genomic
data that we deal with on a daily basis,” said Dr. Robert C. Green. “I
look forward to working with Bina Technologies to help them develop new
products that clinicians and researchers can rely upon for more accurate
and complete data analysis in genomics.”
To learn more about Bina’s Scientific Advisory Board, please see: http://www.binatechnologies.com/company.
In addition to the SAB, Bina is also growing its executive team with two
new hires. Janet Lankard has been hired as VP of Sales, and Gianfranco
de Feo, Ph.D. has joined Bina as VP of Marketing.
“Together, Gianfranco and Janet bring 40 years of deep industry
knowledge to Bina. Each of them have been fundamental in establishing
groundbreaking new technologies, such as qPCR and microarrays, in the
pharmaceutical, basic and clinical research communities,” said Narges
Bani Asadi, CEO of Bina Technologies. “With their help, we’re well on
our way to making good on our mission to bring personalized medicine to
the clinical market.”
Bina Technologies will be demonstrating their latest products at the
Personalized Medicine World Conference from January 27-28. Attendees are
invited to visit the Bina team in Booth #22 in the main exhibition area
of the Computer History Museum in Mountain View, California.
To learn more about Bina Technologies, please visit: http://binatechnologies.com.
About New Members of Bina’s Scientific Advisory Board
Dr. Robert Green
Robert C. Green, MD, MPH is Associate Professor of Medicine in the
Division of Genetics at Brigham and Women’s Hospital and Harvard Medical
School and Associate Director for Research at the Partners HealthCare
Center for Personalized Genetic Medicine. As a practicing physician and
researcher, Dr. Green focuses on addressing the challenges associated
with applying genomics approaches to improve patient care and outcomes.
Dr. Shashikant Kulkarni
Shashikant Kulkarni, Ph.D. is the Director of Cytogenomics and Molecular
Pathology, Director of Clinical Genomics research Unit and an Associate
Professor of Pediatrics, Genetics and Pathology at the Washington
University School of Medicine. Dr. Kulkarni directs a large CAP/CLIA
accredited clinical genomics laboratory that performs breadth of genomic
testing from chromosomes to NGS. His research focuses on identifying
genomic events leading to better treatment of AML and Multiple Myeloma.
Dr. Rong Chen
Dr. Chen is Director of Clinical Genome Informatics at Icahn
Institute of Genetics and Multiscale Biology. He leads Personalized
Cancer Therapy to sequence both DNA and RNA of cancer patients, identify
and integrate genomic alterations and identify driver genes and pathways
to inform effective patient treatment. Dr. Chen, along with the other
new SAB members, has been making strides in bringing large scale
genomics to the clinic.
Dr. Mark Gerstein
Dr. Gerstein is the Albert Williams Professor of Biomedical Informatics,
Molecular Biophysics & Biochemistry and Computer Science at Yale
University. His research involves applying quantitative approaches such
as data mining and simulation to problems in molecular biology, and
genomics. Dr. Gerstein brings extensive experience in informatics and
computation to the Bina scientific advisory board.
About Bina Technologies
Bina is the big data science platform accelerating personalized medicine
for researchers and clinicians requiring fast, accurate and scalable
genomic analysis. We develop cutting-edge big data technologies to
dramatically reduce the amount of time and money required to process raw
genetic data in order to generate insights for personalized medicine.
Founded in 2011, Bina was started by a team of Stanford and Berkeley
researchers and entrepreneurs, with the vision that whole genome
sequencing (WGS) is just the beginning of a brighter future. Bina is
accelerating personalized medicine, one genome at a time.
We are a team of data scientists, bioinformaticians, software developers
and high performance computing experts working in harmony in Redwood
City, California. To learn more, visit: http://binatechnologies.com.
for Bina Technologies
Brittany Smith, 972-809-6832
Source: Bina Technologies